Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Momelotinib · Ojjaara, MMB

Small molecule · Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) · developed by Glaxosmithkline

Approved FDA, Sep 2023
GSK Developer
3 Registered trials

What is Momelotinib?

Momelotinib is an orally available small molecule kinase inhibitor that blocks wild-type JAK1 and JAK2 as well as the mutant JAK2 V617F, reducing JAK-STAT signaling. It also inhibits ACVR1 (ALK2), which lowers hepcidin expression and increases iron availability for red blood cell production. It is used in myelofibrosis, including primary and secondary forms in adults with anemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ojjaara, MMB, CYT-387, GS-0387, CYT-0387, MMB, GS-0387, CYT387
Drug type
Small molecule
Targets
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), activin A receptor type 1 (ALK2) (ACVR1) (secondary target)
Mechanism
Inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2)
Pathways
JAK-STAT signaling, hepcidin inhibition and iron availability, red blood cell production
Therapy area
Hematology
Developer
Glaxosmithkline (GSK)
FDA status
Approved as Ojjaara (September 15, 2023), NDA216873 · FDA label
UNII
6O01GMS00P

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04173494 Phase 3 Primary Myelofibrosis Completed GSK
NCT02515630 Phase 2 Primary Myelofibrosis (PMF) Completed GSK
NCT02258607 Phase 1 Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer Terminated GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Post-Essential Thrombocythemia MyelofibrosisPost-polycythemia Vera (Post-PV) MyelofibrosisPost-Polycythemia Vera MyelofibrosisPostessential Thrombocythemia (Post-ET) MyelofibrosisPrimary MyelofibrosisPrimary Myelofibrosis (PMF)

Other drugs acting on JAK1 / JAK2

More from Glaxosmithkline

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind Momelotinib

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.